<DOC>
	<DOCNO>NCT00065325</DOCNO>
	<brief_summary>The purpose study compare efficacy Faslodex ( fulvestrant ) Aromasin ( exemestane ) hormone receptor positive postmenopausal woman advance breast cancer . Patients treat disease progression investigator determine treatment best interest patient , whichever occur first .</brief_summary>
	<brief_title>The Evaluation Efficacy Tolerability FASLODEX ( Fulvestrant ) AROMASIN ( Exemestane ) Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>Biopsy confirmation Breast Cancer Breast Cancer continue grow receive treatment aromatase inhibitor Postmenopausal woman define woman stop menstrual period Evidence hormone sensitivity Written inform consent participate trial Previous treatment Faslodex ( fulvestrant ) Aromasin ( exemestane ) Any hormonal therapy use modify course additional medical condition prior treatment nonsteroidal aromatase inhibitor Treatment investigational nonapproved drug within one month An exist serious disease , illness , condition prevent participation compliance study procedures A history allergy active inactive ingredient Faslodex Exemestane ( i.e . castor oil Mannitol )</criteria>
	<gender>Female</gender>
	<minimum_age>32 Years</minimum_age>
	<maximum_age>91 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Locally advanced breast cancer</keyword>
	<keyword>metastatic breast cancer</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Cancer Breast</keyword>
	<keyword>Cancer Breast</keyword>
</DOC>